RPHM
Price:
$1.43
Market Cap:
$47.80M
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.[Read more]
Industry
Biotechnology
IPO Date
2021-04-08
Stock Exchange
NASDAQ
Ticker
RPHM
According to Reneo Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.85. This represents a change of -57.62% compared to the average of -2.01 of the last 4 quarters.
The mean historical PE Ratio of Reneo Pharmaceuticals, Inc. over the last ten years is -5.62. The current -0.85 PE Ratio has changed 1.41% with respect to the historical average. Over the past ten years (40 quarters), RPHM's PE Ratio was at its highest in in the September 2001 quarter at 0. The PE Ratio was at its lowest in in the December 2020 quarter at -14.52.
Average
-5.62
Median
-2.52
Minimum
-18.66
Maximum
0
Discovering the peaks and valleys of Reneo Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 98.60%
Maximum Annual PE Ratio = 0
Minimum Annual Increase = -Infinity%
Minimum Annual PE Ratio = -18.66
Year | PE Ratio | Change |
---|---|---|
2023 | -0.63 | -44.37% |
2022 | -1.14 | -70.77% |
2021 | -3.90 | -79.09% |
2020 | -18.66 | 98.60% |
2019 | -9.39 | -Infinity% |
The current PE Ratio of Reneo Pharmaceuticals, Inc. (RPHM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.89
5-year avg
-6.75
10-year avg
-5.62
Reneo Pharmaceuticals, Inc.’s PE Ratio is greater than Prime Medicine, Inc. (-1.95), less than Ginkgo Bioworks Holdings, Inc. (-0.32), less than Ocean Biomedical, Inc. (-0.17), less than Royalty Pharma plc (19.23), greater than Immix Biopharma, Inc. (-2.98), less than CNS Pharmaceuticals, Inc. (-0.00), less than Hepion Pharmaceuticals, Inc. (-0.15), less than Freeline Therapeutics Holdings plc (-0.57), less than AVROBIO, Inc. (2.07), greater than Summit Therapeutics Inc. (-53.72), greater than Nkarta, Inc. (-3.62), greater than Cullinan Oncology, Inc. (-6.96), less than Kezar Life Sciences, Inc. (-0.41), less than Kronos Bio, Inc. (-0.58), greater than Adaptive Biotechnologies Corporation (-2.95), greater than Legend Biotech Corporation (-30.94), greater than Vir Biotechnology, Inc. (-2.19), greater than Apellis Pharmaceuticals, Inc. (-15.28), greater than Werewolf Therapeutics, Inc. (-1.64), greater than Edgewise Therapeutics, Inc. (-14.14), greater than Decibel Therapeutics, Inc. (-1.94), greater than Celcuity Inc. (-7.01), greater than C4 Therapeutics, Inc. (-3.44),
Company | PE Ratio | Market cap |
---|---|---|
-1.95 | $426.11M | |
-0.32 | $975.05M | |
-0.17 | $33.96M | |
19.23 | $12.86B | |
-2.98 | $54.08M | |
-0.00 | $4.60M | |
-0.15 | $4.20M | |
-0.57 | $28.28M | |
2.07 | $5.24M | |
-53.72 | $8.89B | |
-3.62 | $375.37M | |
-6.96 | $1.04B | |
-0.41 | $40.82M | |
-0.58 | $59.36M | |
-2.95 | $629.71M | |
-30.94 | $9.90B | |
-2.19 | $1.06B | |
-15.28 | $5.00B | |
-1.64 | $88.28M | |
-14.14 | $1.64B | |
-1.94 | $123.37M | |
-7.01 | $557.67M | |
-3.44 | $374.42M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Reneo Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Reneo Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Reneo Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Reneo Pharmaceuticals, Inc. (RPHM)?
What is the highest PE Ratio for Reneo Pharmaceuticals, Inc. (RPHM)?
What is the 3-year average PE Ratio for Reneo Pharmaceuticals, Inc. (RPHM)?
What is the 5-year average PE Ratio for Reneo Pharmaceuticals, Inc. (RPHM)?
How does the current PE Ratio for Reneo Pharmaceuticals, Inc. (RPHM) compare to its historical average?